Trial Profile
A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Trevogrumab (Primary) ; Trevogrumab (Primary)
- Indications Muscular atrophy
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 12 Jun 2014 New trial record